



**LOS ANGELES COUNTY DEPARTMENT OF HEALTH SERVICES
CORE PHARMACY & THERAPEUTICS COMMITTEE**

January 12th, 2017

TO: DHS Core P&T Committee
MHLA Clinics

FROM: Amy Gutierrez, Pharm.D.
Jeffrey Guterman, M.D.
Chairs, DHS Core Pharmacy and Therapeutics Committee

RE: December 2016 MHLA Formulary Decisions

MY HEALTH LA FORMULARY

New Drug Additions

Drug Product	Comments
Dolutegravir (Tivicay®) 50mg oral tablet	Added to MHLA 340B Formulary Restricted to HIV post-exposure prophylaxis in combination with Tenofovir-Emtricitabine per CDC guidelines for 28 days. <i>Prior Authorization required.</i>

Formulary Changes

Drug Product	Comments
Tenofovir-Emtricitabine (Truvada®) 300mg-200mg oral tablet	Added restriction. Restricted to HIV pre-exposure prophylaxis (PrEP) per CDC guidelines, OR HIV post-exposure prophylaxis (PEP) in combination with Dolutegravir per CDC guidelines for 28 days. <i>Patient Assistance Program application required for PrEP. Prior Authorization required for PEP.</i>

This document contains confidential information intended for Los Angeles County and MHLA health professionals/employees only. Unintended recipients may not disclose, copy, distribute, or take any action based on this document. This information is not to be disclosed to pharmaceutical representatives, press, or other outside agents.